Annie Luetkemeyer

Professor

Interests:
HIV therapeutic strategies, COVID-19 treatment and prevention, Sexually Transmitted Infections, DoxyPEP, Viral hepatitis, Hepatitis C, Hepatitis Elimination

Clinical Trials:
Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide
Start Date: May 2021
Estimated Completion Date: Oct 2023
Recruitment Status: Recruiting
Condition(s): HIV/AIDS

Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
Start Date: Nov 2019
Estimated Completion Date: May 2023
Recruitment Status: Active, not recruiting
Condition(s): Gonorrhea,Chlamydia,Sexually Transmitted Infections,Syphilis,HIV-Associated Dementia,HIV/AIDS,PrEP

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Start Date: Feb 2016
Completion Date: Mar 2017
Recruitment Status: Terminated
Condition(s): HIV/AIDS,Hepatitis C

A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C
Start Date: Aug 2014
Estimated Completion Date: Dec 2015
Recruitment Status: Withdrawn
Condition(s): Hepatitis C,HIV/AIDS,Fibrosis,HIV-Associated Dementia

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects
Start Date: May 2012
Completion Date: Feb 2014
Recruitment Status: Completed
Condition(s): Tuberculosis

Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection
Start Date: Apr 2008
Completion Date: May 2010
Recruitment Status: Completed
Condition(s): HIV/AIDS,Hepatitis B

Academic Senate:
COVID Faculty Support Committee Member 2022-2023
COVID Faculty Support Committee Member 2021-2022

Education
Fellowship, 2007 - Infectious Diseases, University of California, San Francisco
2006 - Advance Training in Clinical Research, University of California, San Francisco
2003 - Internal Medicine, University of California, San Francisco
2002 - Internal Medicine, University of California, San Francisco
MD, 1999 - Medicine, Harvard Medical School
AB, 1994 - American Studies, Stanford University
Websites
Publications

  1. Tantalo LC, Luetkemeyer A, Lieberman NAP, Nunley BE, Avendaño C, Greninger AL, Celum C, Giacani L. Long-term in vitro exposure of Treponema pallidum to sub-bactericidal doxycycline did not induce resistance: Implications for doxy-PEP and syphilis. The Journal of infectious diseases 2024. PMID: 39067061


  2. Tantalo LC, Luetkemeyer A, P Lieberman NA, Nunley BE, Avendaño C, Greninger AL, Celum C, Giacani L. Long-term in vitro exposure of Treponema pallidum to sub-bactericidal doxycycline did not induce resistance: Implications for doxy-PEP and syphilis. bioRxiv : the preprint server for biology 2024. PMID: 38979216


  3. Morris MD, McDonell C, Luetkemeyer AF, Thawley R, McKinney J, Price JC. Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial. JAMA network open 2023. PMID: 37862013


  4. Luetkemeyer AF, Cannon C, Celum C. Postexposure Doxycycline for Sexually Transmitted Infections. Reply. The New England journal of medicine 2023. PMID: 37467511


  5. Ortega-Villa AM, Hynes NA, Levine CB, Yang K, Wiley Z, Jilg N, Wang J, Whitaker JA, Colombo CJ, Nayak SU, Kim HJ, Iovine NM, Ince D, Cohen SH, Langer AJ, Wortham JM, Atmar RL, El Sahly HM, Jain MK, Mehta AK, Wolfe CR, Gomez CA, Beresnev T, Mularski RA, Paules CI, Kalil AC, Branche AR, Luetkemeyer A, Zingman BS, Voell J, Whitaker M, Harkins MS, Davey RT, Grossberg R, George SL, Tapson V, Short WR, Ghazaryan V, Benson CA, Dodd LE, Sweeney DA, Tomashek KM. Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case. Open forum infectious diseases 2023. PMID: 37383244


  6. Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden LR, Frey S, Whitaker J, Little S, Anderson E, Walter E, Novak R, Rupp R, Jackson L, Babu T, Kottkamp A, Luetkemeyer A, Immergluck L, Presti R, Backer M, Winokur P, Mahgoub S, Goepfert P, Fusco D, Malkin E, Bethony J, Walsh E, Graciaa D, Samaha H, Sherman A, Walsh S, Abate G, Oikonomopoulou Z, Sahly HE, Martin T, Kamidani S, Smith M, Ladner B, Porterfield L, Dunstan M, Wald A, Davis T, Atmar R, Mulligan M, Lyke K, Posavad C, Meagher M, Stephens D, Neuzil K, Abebe K, Hill H, Albert J, Telu K, Mu J, Lewis T, Giebeig L, Eaton A, Netzl A, Wilks S, Tureli S, Makhene M, Crandon S, Montefiori D, Makowski M, Smith D, Nayak S, Roberts P, Beigel J. Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial. Research square 2023. PMID: 37205592


  7. Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, Wu D, Agarwal A, Avendaño-Solá C, Bainbridge E, Bar KJ, Devos T, Duarte RF, Gharbharan A, Hsue PY, Kumar G, Luetkemeyer AF, Meyfroidt G, Nicola AM, Mukherjee A, Ortigoza MB, Pirofski LA, Rijnders BJA, Rokx C, Sancho-Lopez A, Shaw P, Tebas P, Yoon HA, Grudzen C, Hochman J, Antman EM. Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis. 2022. PMID: 35076699


  8. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC. Remdesivir for the Treatment of Covid-19 - Preliminary Report. The New England journal of medicine 2020. PMID: 32445440


  9. Sulkowski M, Luetkemeyer AF, Wyles DL, Martorell C, Muir A, Weisberg I, Gordon SC, McLain R, Huhn G. Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. Alimentary pharmacology & therapeutics 2020. PMID: 32352586


  10. Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019. PMID: 31220220


  11. Silva CAM, Graham B, Webb K, Ashton LV, Harton M, Luetkemeyer AF, Bokatzian S, Almubarak R, Mahapatra S, Hovind L, Kendall MA, Havlir D, Belisle JT, De Groote MA. A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2019. PMID: 31009738


  12. Gaudino A, Gay B, Garmon C, Selick M, Vreeland R, Burk K, Huriaux E, Facente SN, Luetkemeyer A, Waters P, Graham CS. Localized US Efforts to Eliminate Hepatitis C. Infectious disease clinics of North America 2018. PMID: 29778257


  13. Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. Liver international : official journal of the International Association for the Study of the Liver 2017. PMID: 29091342


  14. Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang HC, Butterton J, Robertson M, Wahl J, Barr E, Joeng HK, Martin E, Serfaty L. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. Hepatology (Baltimore, Md.) 2017. PMID: 28688129


  15. Woodworth MH, Marquez C, Chambers H, Luetkemeyer A. Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome. Open forum infectious diseases 2017. PMID: 28959701


  16. Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, Escada RODS, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator DA, Luetkemeyer AF. Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis. Journal of clinical medicine 2017. PMID: 28783093


  17. Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. Open forum infectious diseases 2017. PMID: 28948180


  18. Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017. PMID: 28369210


  19. Wyles DL, Luetkemeyer AF. Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens. Topics in antiviral medicine 2017. PMID: 28820725


  20. Luetkemeyer AF, Wyles DL. CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis. Topics in antiviral medicine 2017. PMID: 28598793


  21. Nelson M, Rubio R, Lazzarin A, Romanova S, Luetkemeyer A, Conway B, Molina JM, Xu D, Srinivasan S, Portsmouth S. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2017. PMID: 28282271


  22. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals of internal medicine 2016. PMID: 27537841


  23. Saharia KK, Petrovas C, Ferrando-Martinez S, Leal M, Luque R, Ive P, Luetkemeyer A, Havlir D, Koup RA. Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells. PloS one 2016. PMID: 27367521


  24. Godfrey C, Tauscher G, Hunsberger S, Austin M, Scott L, Schouten JT, Luetkemeyer AF, Benson C, Coombs R, Swindells S. A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries. BMC infectious diseases 2016. PMID: 27287374


  25. Luetkemeyer AF, Wyles DL. CROI 2016: Viral Hepatitis and Liver Fibrosis. Topics in antiviral medicine 2016. PMID: 27398862


  26. Marquez C, Chamie G, Achan J, Luetkemeyer AF, Kyohere M, Okiring J, Dorsey G, Kamya MR, Charlebois ED, Havlir DV. Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda. Volume 35 of Issue 5. The Pediatric infectious disease journal 2016. PMID: 26771662


  27. Luetkemeyer AF, McDonald C, Ramgopal M, Noviello S, Bhore R, Ackerman P. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016. PMID: 27025835


  28. Luetkemeyer AF, Firnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA, Arduino R, Fernandez M, Guy E, Johnson P, Metchock B, Sattler F, Telzak E, Wang YF, Weiner M, Swindells S, Sanne IM, Havlir DV, Grinsztejn B, Alland D. Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016. PMID: 26839383


  29. Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. Journal of acquired immune deficiency syndromes (1999) 2016. PMID: 26761518


  30. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. The New England journal of medicine 2015. PMID: 26196502


  31. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. The New England journal of medicine 2015. PMID: 26196665


  32. Lee SA, Plett SK, Luetkemeyer AF, Borgo GM, Ohliger MA, Conrad MB, Cookson BT, Sengupta DJ, Koehler JE. Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification. Journal of clinical microbiology 2015. PMID: 26063867


  33. Luetkemeyer AF, Wyles DL. CROI 2015: Highlights of Viral Hepatitis Therapy. Topics in antiviral medicine 2015. PMID: 25965313


  34. Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015. PMID: 25722197


  35. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014. PMID: 25038354


  36. Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrobial agents and chemotherapy 2014. PMID: 24957823


  37. Luetkemeyer AF, Havlir DV, Currier JS. CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy. Topics in antiviral medicine 2014. PMID: 24901886


  38. Chamie G, Marquez C, Luetkemeyer A. HIV-associated central nervous system tuberculosis. Volume 34 of Issue 1. Seminars in neurology 2014. PMID: 24715493


  39. Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. Journal of acquired immune deficiency syndromes (1999) 2014. PMID: 24226057


  40. Marks KM, Kitch D, Chung RT, Hadigan C, Andersen J, Tien P, Luetkemeyer A, Alston-Smith B, Glesby MJ. Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. Journal of acquired immune deficiency syndromes (1999) 2014. PMID: 24525470


  41. Luetkemeyer AF, Kendall MA, Wu X, Lourenço MC, Jentsch U, Swindells S, Qasba SS, Sanchez J, Havlir DV, Grinsztejn B, Sanne IM, Firnhaber C. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. Journal of clinical microbiology 2014. PMID: 24430455


  42. Amorosa VK, Luetkemeyer A, Kang M, Johnson VA, Umbleja T, Haas DW, Yesmin S, Bardin MC, Chung RT, Alston-Smith B, Tebas P, Peters MG. Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. Volume 14 of Issue 6. HIV clinical trials 2013. PMID: 24334180


  43. Chamie G, Wandera B, Luetkemeyer A, Bogere J, Mugerwa RD, Havlir DV, Charlebois ED. Household ventilation and tuberculosis transmission in Kampala, Uganda. Volume 17 of Issue 6. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2013. PMID: 23676159


  44. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013. PMID: 23592830


  45. Luetkemeyer AF, Havlir DV, Currier JS. CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy. Topics in antiviral medicine 2013. PMID: 23681961


  46. Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Topics in antiviral medicine 2012. PMID: 22710907


  47. Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG. Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia. Volume 58 of Issue 3. Journal of acquired immune deficiency syndromes (1999) 2011. PMID: 22005002


  48. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. The New England journal of medicine 2011. PMID: 22010914


  49. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. American journal of respiratory and critical care medicine 2011. PMID: 21737585


  50. Luetkemeyer AF, Getahun H, Chamie G, Lienhardt C, Havlir DV. Tuberculosis drug development: ensuring people living with HIV are not left behind. Volume 184 of Issue 10. American journal of respiratory and critical care medicine 2011. PMID: 21868507


  51. Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Topics in antiviral medicine 2011. PMID: 21868823


  52. Luetkemeyer AF. Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States. Topics in HIV medicine : a publication of the International AIDS Society, USA 2010. PMID: 21107014


  53. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, Havlir DV, Charlebois ED. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Volume 14 of Issue 10. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2010. PMID: 20843421


  54. Chamie G, Luetkemeyer A, Charlebois E, Havlir DV. Tuberculosis as part of the natural history of HIV infection in developing countries. Volume 50 Suppl 3. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010. PMID: 20397955


  55. Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral treatment. Topics in HIV medicine : a publication of the International AIDS Society, USA 2010. PMID: 20516525


  56. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. American journal of respiratory and critical care medicine 2007. PMID: 17218620


  57. Swaminathan S, Luetkemeyer A, Srikantiah P, Lin R, Charlebois E, Havlir DV. Antiretroviral therapy and TB. Tropical doctor 2006. PMID: 16611437


  58. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. Volume 41 of Issue 1. Journal of acquired immune deficiency syndromes (1999) 2006. PMID: 16340470


  59. Schwarz EB, Luetkemeyer A, Foster DG, Weitz TA, Lindes D, Stewart FH. Willing and able? Provision of medication for abortion by future internists. Women's health issues : official publication of the Jacobs Institute of Women's Health 2005. PMID: 15661586